应用UGRP1预测Graves病患者碘131治疗发生甲减风险
|
摘要
目的探讨格雷夫斯病(GD)患者甲状腺细胞子宫球蛋白相关蛋白1(UGRP1)的表达与碘131(~(131)I)治疗后甲状腺功能减退症(甲减)发生风险之间的关系。方法 38例拟行~(131)I治疗的GD患者,通过免疫组化方法检测甲状腺穿刺细胞学所取甲状腺细胞UGRP1的表达,分为UGRP1阳性组(20例)和UGRP1阴性组(18例),~(131)I治疗后12周随访甲状腺功能,分别计算两组的甲减发生率。结果 UGRP1阳性组采用~(131)I治疗,甲减发生率75%;UGRP1阴性组采用~(131)I治疗,甲减发生率33%,两组比较差异有统计学意义(P<0.01)。结论 UGRP1阳性表达组采用~(131)I治疗甲减发生风险较阴性表达组高,提示可以根据UGRP1的表达情况预测GD患者~(131)I治疗发生甲减风险。
Objective To study the relationship between the expression of UGRP1 in thyroid cells of patients with Graves' disease and the probability of hypothyroidism after iodine-131 treatment. Methods Immunohistochemical method was used to detect the expression of UGRP1 in thyroid cells of 38 patients with Graves' disease by fine needle aspiration biopsy(FNAB) prior to the treatment of iodine-131. The thyroid was followed up 12 weeks after iodine-131 treatment. The incidences of hypothyroidism in the UGRP1-positive group of thyroid cells and the UGRP1-negative group were calculated respectively. Results After treated with iodine-131, the incidence of hypothyroidism in the UGRP1-positive expression group was 75%, and the UGRP1-negative expression group was 33%. There was significant difference between the two groups(P<0.01). Conclusion The incidence of hypothyroidism in UGRP1-positive expression group is higher than that in negative expression group, which suggests that the positive expression of UGRP1 in thyroid cells can be used to predict the risk of hypothyroidism in patients of Graves' disease treated with iodine-131.
Objective To study the relationship between the expression of UGRP1 in thyroid cells of patients with Graves' disease and the probability of hypothyroidism after iodine-131 treatment. Methods Immunohistochemical method was used to detect the expression of UGRP1 in thyroid cells of 38 patients with Graves' disease by fine needle aspiration biopsy(FNAB) prior to the treatment of iodine-131. The thyroid was followed up 12 weeks after iodine-131 treatment. The incidences of hypothyroidism in the UGRP1-positive group of thyroid cells and the UGRP1-negative group were calculated respectively. Results After treated with iodine-131, the incidence of hypothyroidism in the UGRP1-positive expression group was 75%, and the UGRP1-negative expression group was 33%. There was significant difference between the two groups(P<0.01). Conclusion The incidence of hypothyroidism in UGRP1-positive expression group is higher than that in negative expression group, which suggests that the positive expression of UGRP1 in thyroid cells can be used to predict the risk of hypothyroidism in patients of Graves' disease treated with iodine-131.
引文
[1]Bahn Chair R S,Burch H B,Cooper D S,et al.Hyperthyroidism and other causes of thyrotoxicosis:management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists[J].Thyroid,2011,21(6):593-646.
[2]Yang D,Xue J,Ma W,et al.Prognostic factor analysis in 325patients with Graves'disease treated with radioiodine therapy[J].Nucl Med Commun,2018,39(1):16-21.
[3]Sfiligoj D,Gaberscek S,Mekjavic P J,et al.Factors influencing the success of radioiodine therapy in patients with Graves'disease[J].Nucl Med Commun,2015,36(6):560-5.
[4]Niimi T,Keck-Waggoner C L,Popescu N C,et al.UGRP1,a uteroglobin/Clara cell secretory protein-related protein,is a novel lung-enriched downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor[J].Mol Endocrinol,2001,15(11):2021-36.
[5]Song H D,Liang J,Shi J Y,et al.Functional SNPs in the SCGB3A2 promoter are associated with susceptibility to Graves'disease[J].Hum Mol Genet,2009,18(6):1156-70.
[6]中华医学会核医学分会.131Ⅰ治疗格雷夫斯甲亢指南(2013版)[J].中华内分泌代谢杂志,2013,29(6):448-59.
[7]Sheehan M T,Doi S A.Transient hypothyroidism after radioiodine for Graves'disease:challenges in interpreting thyroid function tests[J].Clin Med Res,2016,14(1):40-5.
[8]Niimi T,Munakata M,Keck-waggoner C L,et al.A polymorphism in the human UGRP1 gene promoter that regulates transcription is associated with an increased risk of asthma[J].Am J Hum Genet,2002,70(3):718-25.
[9]Kido T,Yoneda M,Cai Y,et al.Secretoglobin superfamily protein SCGB3A2 deficiency potentiates ovalbumin-induced allergic pulmonary inflammation[J].Mediators Inflamm,2014,2014(1):216465.
[10]Yoneda M,Xu L,Kajiyama H,et al.Secretoglobin superfamily protein SCGB3A2 alleviates house dust mite-induced allergic airway inflammation in mice[J].Int Arch Allergy Immunol,2016,171(1):36-44.
[11]Chiba Y,Srisodsai A,Supavilai P,et al.Interleukin-5 reduces the expression of uteroglobin-related protein(UGRP)1 gene in allergic airway inflammation[J].Immunol Lett,2005,97(1):123-9.
[12]Chiba Y,Kusakabe T,Kimura S.Decreased expression of uteroglobin-related protein 1 in inflamed mouse airways is mediated by IL-9[J].Am J Physiol Lung Cell Mol Physiol,2004,287(6):L1193-8.
[13]Srisodsai A,Kurotani R,Chiba Y,et al.Interleukin-10 induces uteroglobin-related protein(UGRP)1 gene expression in lung epithelial cells through homeodomain transcription factor T/EBP/NKX2.1[J].J Biol Chem,2004,279(52):54358-68.
[2]Yang D,Xue J,Ma W,et al.Prognostic factor analysis in 325patients with Graves'disease treated with radioiodine therapy[J].Nucl Med Commun,2018,39(1):16-21.
[3]Sfiligoj D,Gaberscek S,Mekjavic P J,et al.Factors influencing the success of radioiodine therapy in patients with Graves'disease[J].Nucl Med Commun,2015,36(6):560-5.
[4]Niimi T,Keck-Waggoner C L,Popescu N C,et al.UGRP1,a uteroglobin/Clara cell secretory protein-related protein,is a novel lung-enriched downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor[J].Mol Endocrinol,2001,15(11):2021-36.
[5]Song H D,Liang J,Shi J Y,et al.Functional SNPs in the SCGB3A2 promoter are associated with susceptibility to Graves'disease[J].Hum Mol Genet,2009,18(6):1156-70.
[6]中华医学会核医学分会.131Ⅰ治疗格雷夫斯甲亢指南(2013版)[J].中华内分泌代谢杂志,2013,29(6):448-59.
[7]Sheehan M T,Doi S A.Transient hypothyroidism after radioiodine for Graves'disease:challenges in interpreting thyroid function tests[J].Clin Med Res,2016,14(1):40-5.
[8]Niimi T,Munakata M,Keck-waggoner C L,et al.A polymorphism in the human UGRP1 gene promoter that regulates transcription is associated with an increased risk of asthma[J].Am J Hum Genet,2002,70(3):718-25.
[9]Kido T,Yoneda M,Cai Y,et al.Secretoglobin superfamily protein SCGB3A2 deficiency potentiates ovalbumin-induced allergic pulmonary inflammation[J].Mediators Inflamm,2014,2014(1):216465.
[10]Yoneda M,Xu L,Kajiyama H,et al.Secretoglobin superfamily protein SCGB3A2 alleviates house dust mite-induced allergic airway inflammation in mice[J].Int Arch Allergy Immunol,2016,171(1):36-44.
[11]Chiba Y,Srisodsai A,Supavilai P,et al.Interleukin-5 reduces the expression of uteroglobin-related protein(UGRP)1 gene in allergic airway inflammation[J].Immunol Lett,2005,97(1):123-9.
[12]Chiba Y,Kusakabe T,Kimura S.Decreased expression of uteroglobin-related protein 1 in inflamed mouse airways is mediated by IL-9[J].Am J Physiol Lung Cell Mol Physiol,2004,287(6):L1193-8.
[13]Srisodsai A,Kurotani R,Chiba Y,et al.Interleukin-10 induces uteroglobin-related protein(UGRP)1 gene expression in lung epithelial cells through homeodomain transcription factor T/EBP/NKX2.1[J].J Biol Chem,2004,279(52):54358-68.